Core-shell type star polymer bearing carboxylate functions was designed and evaluated as nanocarrier of cisplatin. The synthetic route to the star macromolecules involved the "core first" method to yield a precursor star polymer with a highly branched poly(styrene) core and poly(tert-butyl acrylate) arms. Two polymers derived from a common core of M(n) = 2400 g/mol and degrees of polymerization of the linear arms 38 and 58 were subjected to acidic hydrolysis to obtain stars with a hydrophilic and multifunctional shell. Diffusion ordered NMR spectroscopic study revealed that the two products presented single populations of stars with values of the apparent hydrodynamic radii 12.9 nm and 14.0 nm, respectively. The stars were loaded with cisplatin via ligand exchange reaction achieving remarkable high drug payload of 45% (w/w). The conjugates were stable in an aqueous solution exhibiting no precipitation for a prolonged period of time. The release profile of the platinum (II) complexes in phosphate buffered saline and RPMI-1640 liquid medium at 37 °C indicated sustained manner of drug release with no initial burst effect. In vitro cell viability study, using four human tumor cell lines proved that the conjugates exhibited lower cytotoxicity compared to the free agent. The established cellular accumulation of cisplatin indicated uptake of the nanoconjugates by the cells through endocytosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2010.11.004DOI Listing

Publication Analysis

Top Keywords

high drug
8
drug payload
8
star polymer
8
star-shaped nano-conjugates
4
cisplatin
4
nano-conjugates cisplatin
4
cisplatin high
4
payload core-shell
4
core-shell type
4
type star
4

Similar Publications

Distinct molecular subtypes of muscle-invasive bladder cancer (MIBC) may show different platinum sensitivities. Currently available data were mostly generated at transcriptome level and have limited comparability to each other. We aimed to determine the platinum sensitivity of molecular subtypes by using the protein expression-based Lund Taxonomy.

View Article and Find Full Text PDF

Objective: Colorectal Cancer (CRC) has attracted much attention due to its high mortality and morbidity. Cordycepin, also known as 3'-deoxyadenosine (3'-dA), exhibits many biological functions, including antibacterial, anti-inflammatory, antiviral, anti-tumor, and immunomodulatory effects. It has been proven to show anticancer activity in both laboratory research studies and living organisms.

View Article and Find Full Text PDF

Background: Lenvatinib is an oral tyrosine kinase inhibitor that selectively inhib-its receptors involved in tumor angiogenesis and tumor growth. It is an emerging first-line treatment agent for hepatocellular carcinoma (HCC). However, there is no intravenous ad-ministration of Lenvatinib.

View Article and Find Full Text PDF

Background: Breast cancer is a frequently diagnosed malignant disease and the primary cause of mortality among women with cancer worldwide. The therapy options are influenced by the molecular subtype due to the intricate nature of the condition, which consists of various subtypes. By focusing on the activation of receptors, Epidermal Growth Factor Receptor (EGFR) tyrosine kinase can be utilized as an effective drug target for therapeutic purposes of breast cancer.

View Article and Find Full Text PDF

Aims: This study aimed to develop Imatinib Mesylate (IMT)-loaded Poly Lactic-co-Glycolic Acid (PLGA)-D-α-tocopheryl polyethylene glycol succinate (TPGS)- Polyethylene glycol (PEG) hybrid nanoparticles (CSLHNPs) with optimized physicochemical properties for targeted delivery to glioblastoma multiforme.

Background: Glioblastoma multiforme (GBM) is the most destructive type of brain tumor with several complications. Currently, most treatments for drug delivery for this disease face challenges due to the poor blood-brain barrier (BBB) and lack of site-specific delivery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!